#AbbVie #pain therapy #Haisco

Haisco Partners with AbbVie for Development of Pain Relief Medications

Haisco Pharmaceutical Group Co., Ltd., a notable player in innovative pharmaceuticals, recently announced its exclusive licensing agreement with AbbVie, a leading global biopharmaceutical company. This significant collaboration aims to enhance the development of novel medications targeting pain relief, expanding both companies' footprints in the healthcare sector.

On April 10, 2026, this partnership was formalized, allowing AbbVie to take the lead in the development, manufacturing, and commercialization of these cutting-edge pain treatments. Importantly, the agreement provides AbbVie with exclusive rights outside of China, Hong Kong, and Macau, marking a strategic international step for Haisco.

The Development Pipeline

The licensing agreement encompasses a variety of compounds that address several pain-related indications. These compounds are currently at different stages of development in China, ranging from preclinical studies to Phase 1 clinical trials. This structured approach ensures that innovative solutions for pain management are developed efficiently and effectively.

Dr. Pangke Yan, CEO of Haisco, expressed enthusiasm about the collaboration, stating, "This partnership aligns seamlessly with our strategy for international development. We anticipate that it will create sustainable value and long-term returns." Haisco aims to expedite the global rollout of innovative pain therapies by leveraging AbbVie’s expertise and resources in neuroscience, thus ensuring high-quality treatment options are delivered to patients globally.

Financial Aspects of the Agreement

As part of this collaborative effort, Haisco will receive an initial payment of USD $30 million. Additionally, the company stands to benefit from a complex performance-based structure worth up to USD $715 million, which includes developmental, regulatory, and commercial milestones. Haisco also has the potential to earn royalties based on future sales, demonstrating the lucrative nature of the agreement for both parties involved.

Haisco's Commitment to R&D

Haisco has emerged as a benchmark enterprise in China's pharmaceutical landscape, driven by a core strategy focused on